News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo -- -- Company’s studies also show CCR4 inhibition enhances effectiveness of checkpoint inhibition in tumor models in vivo -- MOUNTAIN VIEW, Calif.
View HTML
Toggle Summary ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference
MOUNTAIN VIEW, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 8:30 a.m. ET .
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights
-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 – -- $186 million in cash and investments at September 30, 2018 -- -- Received Orphan Drug Designation for CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Conference call today
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018
MOUNTAIN VIEW, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis -- -- Reveals Potential New Role for Chemokine Receptor 2 (CCR2) in the Treatment of Focal Segmental Glomerulosclerosis (FSGS) with First
View HTML
Toggle Summary ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
View HTML
Toggle Summary ChemoCentryx Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to
View HTML
Toggle Summary ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September: 20 th Annual Rodman & Renshaw Global Investment
View HTML
Toggle Summary ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Launch of clinical
View HTML